uniQure N.V.
NASDAQ:QURE
Overview | Financials
| Company Name | uniQure N.V. |
| Symbol | QURE |
| Currency | USD |
| Price | 17.43 |
| Market Cap | 956,330,067 |
| Dividend Yield | 0% |
| 52-week-range | 4.45 - 19.18 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Matthew Craig Kapusta |
| Website | https://www.uniqure.com |
An error occurred while fetching data.
About uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD







